GSK Launches Sri Lanka's First Targeted Treatment For Renal Cell Cancer
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline said it has launched in Sri Lanka its Votrient (pazopanib) drug for treating renal cell carcinoma as the country's first targeted therapy for the disease responsible for 90% of kidney cancers.